Unlocking Major Targets with Mini Proteins

Episode Summary

Executive Summary: ScapeBio is using AI-guided de novo protein design to create mini-protein therapeutics that target hard-to-drug GPCRs in their native cellular environment. CEO Christopher Norn says mini-proteins can combine antibody-like selectivity with small-molecule-like stability and deeper receptor engagement, enabling agonists and antagonists that traditional modalities struggle to make. The company has validated its platform across 11 GPCRs and is advancing an internal pipeline toward in vivo studies.

Main Topics: Why GPCRs are difficult to drug (Priority: 5/5): The discussion explains that many GPCRs remain inaccessible because antibodies are hard to generate against membrane proteins and often lose function when receptors are removed from their native lipid context; small molecules also suffer from selectivity and safety limitations. Mini-proteins as a new drug modality (Priority: 5/5): Norn describes mini-proteins as an ideal modality that can offer antibody-like selectivity, small-molecule-like stability, and precise sequence control, while being able to penetrate GPCR pockets and lock receptors into desired conformations. AI-enabled design and screening workflow (Priority: 5/5): Scape uses LLMs for target prioritization, protein-design methods such as RF diffusion and scaffold libraries for backbone generation, and human-cell screening in native receptor environments to identify binders and functional modulators. Platform validation and pipeline progress (Priority: 4/5): The company claims robust validation across 11 GPCRs, including agonists, antagonists, and binders, with picomolar potency examples and a lead program in migraine. It is now transitioning from platform build-out to asset advancement. Founding story and enabling ecosystem (Priority: 4/5): The company emerged from Christopher Norn's postdoctoral work in David Baker's lab and support from the BioInnovation Institute, which funded technology development before company launch. Commercial strategy, financing, and differentiation (Priority: 4/5): Scape is positioning itself as both a platform and pipeline company, with partnering opportunities, seed financing underway, and differentiation rooted in proprietary high-throughput screening plus know-how rather than AI alone.

Key Arguments: GPCRs are a large, clinically important target class, but most remain undrugged because current modalities do not reliably generate safe, selective, functional modulators. Mini-proteins can reach deeper into GPCR binding pockets than antibodies and can be designed to stabilize specific receptor conformations, enabling activation or inhibition. Keeping receptors in their native human-cell membrane environment during screening helps preserve functional conformations that are often lost in traditional antibody-generation workflows. LLMs and other AI tools help systematize target selection across many indications and modes of action, reducing subjective, debate-heavy prioritization. Scape’s platform has been experimentally validated, not just computationally, through repeated success across multiple GPCRs and pharmacological hit generation. The most important near-term risk for mini-proteins is half-life and immunogenicity, both of which the company says it is actively addressing through conjugation and monitoring. The company believes the major value now lies in advancing specific therapeutic assets into in vivo efficacy studies rather than further platform expansion.

Data Points: GPCRs validated by Scape: 11 - Norn says the company has generated modulators for 11 different GPCRs in collaboration with the Baker Lab. Agonist targets generated: 3 - He states Scape has made agonists against three different GPCR targets. Mini-protein length: 40 to 70 amino acids - Used to contrast mini-proteins with much larger Y-shaped antibodies. Antibody vs mini-protein size comparison: About 15 times longer - Norn describes antibodies as roughly fifteen times longer than mini-proteins. Mini-protein half-life without conjugation: 10 to 20 minutes - He says unmodified mini-proteins are typically eliminated quickly. Targets screened in native-environment platform: 3 targets - Scape says its human-cell screening platform has been used against three targets. Target/opportunity assessment scale: 8 dimensions - The team initially scored targets across multiple criteria before using LLMs to systematize the process. Explored opportunities with LLMs: 3,000 - Norn says they evaluated approximately 3,000 target indication/mode-of-action opportunities. Current shortlisted indications/modes of action: Around 8 - AI helped narrow the field to a smaller set of best-fit opportunities. Funding status: Seed round underway - The company says it has raised capital already and is now seeking additional seed financing. Company size: 15 people total - Norn notes the company is operating with a small team in Copenhagen. Development timeline: Next 12 months - He expects leads across many programs to be identified within the coming year. BioInnovation Institute development window: 2.5 years - The team spent about two and a half years establishing and proving the technology before launch.

Pivotal Quotes: "we create these de novo designed biologics entirely from scratch, and we create them with such precision that we can stabilize the side conformations of the receptors and then induce function." — Christopher Norn: Explaining ScapeBio’s core approach to designing GPCR modulators "mini-proteins are sort of an ideal drug modality. They're combining some of the best features from both antibodies and small molecules." — Christopher Norn: Describing why the company chose mini-proteins as its therapeutic platform "the ability to create modulators entirely from scratch with the function that you need is gonna change completely how drug discovery is working." — Christopher Norn: His broader view of the impact of AI-driven protein design on drug discovery

Implications: If Scape’s approach scales, GPCR drug discovery could expand beyond small molecules and a few peptides into a broader class of precise, functional biologics. That could unlock new treatments in validated and genetically linked diseases, especially where selectivity or efficacy has been a barrier.